中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 2
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(2): 304-308

Value of interleukin-32 combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.02.012

  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China

  • Received Date: 2020-08-07
  • Accepted Date: 2020-09-03
  • Published Date: 2021-02-20
    Abstract
  •   Objective  To investigate the value of interleukin-32 (IL-32) combined with Model for End-Stage Liver Disease (MELD) in predicting the prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF).  Methods  A total of 92 patients with HBV-ACLF who were hospitalized in The First Affiliated Hospital of Soochow University from January 2015 to December 2018 were enrolled, and according to the follow-up results at 3 months after diagnosis, the patients were divided into survival group with 40 patients and death group with 52 patients. ELISA was used to measure the serum level of IL-32. Clinical data of the patients were collected, including age, sex, underlying diseases, major complications, white blood cell count (WBC), platelet count (PLT), hematocrit (HCT), total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (Alb), serum creatinine (SCr), prothrombin time (PT), international normalized ratio (INR), and HBV DNA. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups; a Pearson correlation analysis was performed for IL-32 and other variables; a binary logistic regression analysis was performed to investigate the independent risk factors for the prognosis of patients with HBV-ACLF. The receiver operating characteristic(ROC) curve(AUC) was used to evaluate the value of IL-32 combined with MELD score in predicting the prognosis of patients with HBV-ACLF. The normal Z test was used for comparison of AUC.  Results  There were significant differences between the two groups in HCT, PLT, TBil, SCr, PT, INR, HBV DNA, IL-32, and MELD score (all P < 0.05). IL-32 was positively correlated with TBil (r=0.952, P < 0.001) and MELD score (r=0.850, P < 0.001). IL-32 (odds ratio [OR]=1.137, 95% confidence interval [CI]: 1.040-1.243, P=0.005) and MELD score (OR=1.055, 95% CI: 1.001-1.109, P=0.025) were independent risk factors for the death of HBV-ACLF patients. IL-32 combined with MELD score had the highest value in predicting the prognosis of patients with HBV-ACLF (AUC=0.992, 95% CI: 0.981-1.000), with a significantly higher AUC than IL-32 (0.992 vs 0.984, Z=2.265, P < 0.05) and MELD score (0.992 vs 0.877, Z=3.182, P < 0.05).  Conclusion  Both IL-32 and MELD score can predict the prognosis of patients with HBV-ACLF, and the combination of these two indicators has a better predictive value.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3
    [2]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artifical Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.01.007

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J].临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007
    [3]
    LI H, JIA YN, HE Q, et al. Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease[J]. Ogran Transplantation, 2020, 11(3): 344-349. (in Chinese) DOI: 10.3969/j.issn.1674-7445.2020.03.004

    李瀚, 贾亚男, 贺强, 等. 危重症肝病肝移植术后免疫抑制剂管理和感染的防治进展[J]. 器官移植, 2020, 11(3): 344-349. DOI: 10.3969/j.issn.1674-7445.2020.03.004
    [4]
    SUNDARAM V, JALAN R, WU T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation[J]. Gastroenterology, 2019, 156(5): 1381-1391. DOI: 10.1053/j.gastro.2018.12.007
    [5]
    XU J, HUANG M. Predictive value of plasma diamine oxidase concentration combined with iMELD score on short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure[J/CD].Chin J Liver Dis (Electronic Version), 2020, 12(2): 68-75. (in Chinese)

    许俊, 黄敏. 血浆二胺氧化酶联合iMELD评分对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的预测价值[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(2): 68-75.
    [6]
    ALBILLOS A, LARIO M, ÁLVAREZ-MON M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance[J]. J Hepatol, 2014, 61(6): 1385-1396. DOI: 10.1016/j.jhep.2014.08.010
    [7]
    RIBEIRO-DIAS F, SAAR GOMES R, de LIMA SILVA LL, et al. Interleukin 32: A novel player in the control of infectious diseases[J]. J Leukoc Biol, 2017, 101(1): 39-52. DOI: 10.1189/jlb.4RU0416-175RR
    [8]
    XU Q, PAN X, SHU X, et al. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver[J]. J Infect, 2012, 65(4): 336-342. DOI: 10.1016/j.jinf.2012.05.009
    [9]
    ZHANG WJ, ZHAO LJ, WU JZ. Value of MELD、AARC、COSSH scoring systems in evaluating the 90-day prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2020, 36(4): 813-817. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.04.021

    张文佳, 赵丽娟, 吴基洲.  MELD、AARC、COSSH评分系统对乙型肝炎相关慢加急性肝衰竭90天预后的评估价值[J]. 临床肝胆病杂志, 2020, 36(4): 813-817. DOI: 10.3969/j.issn.1001-5256.2020.04.021
    [10]
    ZHAO RH, SHI Y, ZHAO H, et al. Acute-on-chronic liver failure in chronic hepatitis B: An update[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(4): 341-350. DOI: 10.1080/17474124.2018.1426459
    [11]
    WU W, YAN H, ZHAO H, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: Differentiate it from No-ACLF[J]. Liver Int, 2018, 38(2): 248-257. DOI: 10.1111/liv.13504
    [12]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740
    [13]
    SOLÉ C, SOLÀ E. Update on acute-on-chronic liver failure[J]. Gastroenterol Hepatol, 2018, 41(1): 43-53. DOI: 10.1016/j.gastrohep.2017.05.012
    [14]
    DALI-YOUCEF N, VIX M, COSTANTINO F, et al. Interleukin-32 contributes to human nonalcoholic fatty liver disease and insulin resistance[J]. Hepatol Commun, 2019, 3(9): 1205-1220. DOI: 10.1002/hep4.1396
    [15]
    GUI M, ZHANG H, ZHONG K, et al. Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis[J]. Asian Pac J Allergy Immunol, 2013, 31(1): 73-78.
    [16]
    YANG Z, SHI L, XUE Y, et al. Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease[J]. Clin Chim Acta, 2019, 497: 104-109. DOI: 10.1016/j.cca.2019.07.019
    [17]
    DI BENEDETTO P, GUGGINO G, MANZI G, et al. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension[J]. Arthritis Res Ther, 2020, 22(1): 127. DOI: 10.1186/s13075-020-02218-8
    [18]
    KOEKEN V, VERRALL AJ, ARDIANSYAH E, et al. IL-32 and its splice variants are associated with protection against Mycobacterium tuberculosis infection and skewing of Th1/Th17 cytokines[J]. J Leukoc Biol, 2020, 107(1): 113-118. DOI: 10.1002/JLB.4AB0219-071R
    [19]
    ZOU Y, BAO J, PAN X, et al. NKP30-B7-H6 interaction aggravates hepatocyte damage through up-regulation of interleukin-32 expression in hepatitis B virus-related acute-on-chronic liver failure[J]. PLoS One, 2015, 10(8): e0134568. DOI: 10.1371/journal.pone.0134568
    [20]
    TIAN ZJ, SHEN Y, LI XR, et al. Increased interleukin-32, interleukin-1, and interferon-γ levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers[J]. J Infect Public Health, 2019, 12(1): 7-12. DOI: 10.1016/j.jiph.2018.06.006
    [21]
    LI ZY, YANG ST, ZHAO CY, et al. Analysis of prognostic risk factors and establishment of prognosis model in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Chin J Infect Dis, 2019, 37(12): 737-741. (in Chinese) DOI: 10.3760/cma.j.issn.1000-6680.2019.12.004

    李子月, 杨士田, 赵彩彦, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者预后危险因素分析及预后模型建立[J]. 中华传染病杂志, 2019, 37(12): 737-741. DOI: 10.3760/cma.j.issn.1000-6680.2019.12.004
    [22]
    ZHANG H, SHI XX, ZENG YL, et al. Clinical study on short-term prognostic value of serum IL-8 level in patients with HBV related acute-on-chronic liver failure[J]. Infect Dis Info, 2020, 33(2): 136-139. (in Chinese) DOI: 10.3969/j.issn.1007-8134.2020.02.009

    张鸿, 石新星, 曾义岚, 等. 血清IL-8预测HBV相关慢加急性肝衰竭患者短期预后的临床研究[J]. 传染病信息, 2020, 33(2): 136-139. DOI: 10.3969/j.issn.1007-8134.2020.02.009
    [23]
    WANG J, WANG Q, GUAN SH, et al. Expression and clinical significance of IL-26 in hepatitis B virus-associated acute-on-chronic liver failure[J]. Acta Universitatis Medicinalis Anhui, 2020, 55(4): 612-617. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YIKE202004025.htm

    汪静, 王琴, 管世鹤, 等. 白细胞介素-26在乙型肝炎相关慢加急性肝衰竭患者中的表达及临床意义[J]. 安徽医科大学学报, 2020, 55(4): 612-617. https://www.cnki.com.cn/Article/CJFDTOTAL-YIKE202004025.htm
    [24]
    FISCHER J, SILVA TE, SOARES E SILVA PE, et al. From stable disease to acute-on-chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis[J]. Cytokine, 2017, 91: 162-169. DOI: 10.1016/j.cyto.2016.12.017
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (466) PDF downloads(43) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return